Amgen Inc. (AMGN) News Today: Latest Market and Industry Updates
360.5
2.54
0.71 %
At close
06/29
USD
Daily range
358.46
363.08
363.08
Weekly range
345.49
363.08
363.08
Amgen edges higher to $347.82 as it joins HHS roundtable on clinical trial access
Amgen expressed appreciation to the U.S. Department of Health and Human Services for organizing a Clinical Trials Roundtable.The company said clinical trials are key to bringing new medicines to ...
Amgen stock consolidates near $348 amid robust Research Triangle growth
Amgen is investing more than $1.5 billion in North Carolina's life sciences ecosystem, the company said on social media.Amgen says the investment contributes to innovation, growth, and opportunity ...
+3.35% for Amgen stock as Gilpin, ING Groep NV, Motley Fool increase holdings
Amgen Inc. (AMGN) stock is trading at $349.04, up 3.35% today. The price currently sits above its key moving averages, reflecting momentum in the current ...
Amgen stock extends rally above $349 with bullish momentum and overbought signals
Amgen shared new data on cardiometabolic care at the #ADASciSessions 2026, the company said in a tweet.Amgen said the data reinforce the need for more integrated approaches to prevention, risk ...
Amgen stock rises 3.05 percent as Amgen leadership explores AI-driven innovation in drug development
Amgen CEO Bob Bradway appeared on Bain and Company's Winning with AI podcast alongside Sarah Elk and AI pioneer Andrew Ng, the company said in a tweet.The discussion covered how AI is accelerating ...
Amgen stock climbs as obesity drug research boosts future pipeline
Amgen Inc. (AMGN) stock is trading at $338.42, up 3.09% today. The price currently sits above its short- and long-term moving averages, indicating support from these ...
Amgen stock edges higher to $330.51 as new data in rare autoimmune diseases presented, Amgen announces
Amgen announced the presentation of new data across rare autoimmune and inflammatory diseases at EULAR2026.The research covers IgG4-related disease and real-world evidence in ANCA-associated ...
Amgen shares dip amid rising selling pressure
Amgen Inc. (AMGN) is trading at $329.33, representing a daily decline of $7.56 or 2.24%. The asset remains just above its 200-day simple moving average ($328.23), while positioned below both the ...
Amgen stock consolidates as earnings per share beats consensus
Amgen Inc. (AMGN) stock is trading at $338.39, down 0.34% on the day and currently positioned above its key short- and long-term moving averages, but below mid-term ...
Amgen stock drops 1.19% as Phase 3 data supports early LDL-C lowering in high-risk CV patients
Amgen presented late-breaking Phase 3 data at ACC’s 2026 conference showing support for earlier intensive LDL-C lowering in high-risk patients without known atherosclerosis.The data suggest ...
Amgen stock consolidates as leaders tout AI in medicine discovery and delivery
Amgen is expanding the use of AI to support how medicines are discovered, developed and delivered. The company shared its approach in a sponsored feature with WIRED.AI tools are on track to help ...
Amgen stock moves lower after Rep Luz Rivas joins Amgen Foundation students
Amgen thanked Representative Luz Rivas for joining Amgen Foundation ABE students in the classroom.The company acknowledged the presence of Rep. Rivas and highlighted the involvement of Amgen ...
Amgen stock forecast for 2030: $6B patent exposure challenges $500 level
In 2026, Amgen will be running two businesses at the same time. Repatha, IMDELLTRA, EVENITY, and TEZSPIRE are all part of a high-growth portfolio that is growing by double digits in volume. The ...
Amgen focuses on early intervention for ASCVD management
Amgen highlights the importance of early-stage intervention in managing atherosclerotic cardiovascular disease (ASCVD). For many patients, a cardiovascular event signals the commencement of ...
Amgen wins full FDA approval for lung cancer therapy
Amgen has secured full approval from the U.S. Food and Drug Administration for its new therapy designed for adults with extensive stage small cell lung cancer who have progressed after ...
Amgen to announce Q3 2025 results on November 4
Amgen has announced that it will release its financial results for the third quarter of 2025 on Tuesday, November 4. This announcement is likely to draw significant interest from investors and ...
